Compare ULBI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULBI | CRDL |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 97.3M |
| IPO Year | 1995 | 2017 |
| Metric | ULBI | CRDL |
|---|---|---|
| Price | $6.93 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 60.7K | ★ 332.6K |
| Earning Date | 06-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1166.67 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $164,456,000.00 | N/A |
| Revenue This Year | $20.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $77.78 | ★ N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $4.07 | $0.77 |
| 52 Week High | $9.51 | $1.59 |
| Indicator | ULBI | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 44.68 |
| Support Level | $6.35 | $0.94 |
| Resistance Level | $7.24 | $1.09 |
| Average True Range (ATR) | 0.46 | 0.05 |
| MACD | 0.17 | -0.00 |
| Stochastic Oscillator | 79.37 | 13.06 |
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.